Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs2684788
rs2684788
0.010 GeneticVariation BEFREE The results of the present study revealed an association between rs1815009, rs2684788 and PCa risk, which involves altered miRNA regulation and contributes to cancer susceptibility. 30365147

2019

dbSNP: rs2928140
rs2928140
0.010 GeneticVariation BEFREE The aim of our study was to investigate single nucleotide polymorphisms (SNPs) in <i>RAD51</i> (rs2619679, rs2928140, and rs5030789) and <i>XRCC3</i> (rs1799796) involved in DNA double-strand break repair and their relationship to prostate cancer. 31186630

2019

dbSNP: rs3181082
rs3181082
0.010 GeneticVariation BEFREE Our results indicated that <i>CD1B</i> rs3181082 confers prostate cancer progression and may help improve clinical prognostic stratification. 31783478

2019

dbSNP: rs3208008
rs3208008
0.010 GeneticVariation BEFREE <i>RTEL1</i> rs2297441 [odds ratio (OR): 1.23; 95% confidence interval (CI): 1.03-1.46, <i>P</i> = 0.021] and rs3208008 (OR: 1.23; 95% CI: 1.03-1.46) were associated with PCa risk. 31762827

2019

dbSNP: rs3761548
rs3761548
0.010 GeneticVariation BEFREE Evaluation of the genetic variations in position SNP rs3761548</span> revealed that the AA genotype and A allele were more prevalent whereas CC genotype and C allele were less prevalent in PC patients when compared with healthy men (P < 0.01, P < 0.001, P < 0.002 and P < 0.001, respectively). 30057362

2019

dbSNP: rs3829078
rs3829078
CA9
0.010 GeneticVariation BEFREE The rs3829078 polymorphic genotype of CA9 can predict the risk of lymph node metastasis of CaP with an initial PSA level ≤10 ng/ml. 31155437

2019

dbSNP: rs4143815
rs4143815
0.010 GeneticVariation BEFREE A polymorphism in the <i>PDL1</i> gene (rs4143815) was the unique potential genetic variant of 10 year BCR (training set: <i>p</i> = 0.003, HR (95% CI) = 0.58 (0.41-0.83); replication set: <i>p</i> = 0.063, HR (95% CI) = 0.52 (0.26-1.04)) that was significantly associated with 5 year BCR (training set: <i>p</i> = 0.009, HR (95% CI) = 0.59 (0.40-0.88); replication set: <i>p</i> = 0.036, HR (95% CI) = 0.39 (0.16-0.94)).No biomarkers of OS were replicated. rs4143815-<i>PDL1</i> arose as a new immunogenetic biomarker of BCR in PCa, giving new insights into the RT/immune system interaction, which could be potentially useful in new approaches using anti-PDL1 therapies for PCa. 31035590

2019

dbSNP: rs4646903
rs4646903
0.010 GeneticVariation BEFREE <b>Conclusion.</b> This meta-analysis revealed a clear association between rs1048943 and rs4646903 polymorphisms of the <i>CYP1A1</i> gene but not between CYP1B1 rs10012, rs162549, rs1800440, and rs2551188 polymorphisms and the risk of PCa. 30765615

2019

dbSNP: rs4705343
rs4705343
0.010 GeneticVariation BEFREE Since miRNA-based mechanisms are shown to be involved in the pathogenesis of prostate cancer (PCa), the aim of the present study was to evaluate the effect of rs4938723, rs1076064 and rs4705343 occurring in regulatory regions of miR-34b/c, miR-143/145 and miR-378, respectively, on PCa risk and progression in Serbian population. 31423132

2019

dbSNP: rs4774388
rs4774388
0.010 GeneticVariation BEFREE The rs11639084 and rs4774388 alleles were not different between PCa and normal groups 95% CI: 0.52-1.24, OR = 1.04, P = .34; 95% CI: 0.48-1.33, OR = .79, P = .39 respectively. 30251751

2019

dbSNP: rs5030789
rs5030789
0.010 GeneticVariation BEFREE A significant association was detected between <i>RAD51</i> rs5030789 polymorphism and <i>XRCC3</i> rs1799796 polymorphism and an increased risk of prostate cancer. 31186630

2019

dbSNP: rs55705857
rs55705857
0.010 GeneticVariation BEFREE First-degree relatives of rs55705857 G allele carriers were at significantly increased risk for developing cancer (RR = 1.72, p = 0.045, CI 1.02-2.94), and specifically for oligodendroglioma (RR = 57.61, p = 0.017, CI 2.96-320.98) or prostate cancer (RR = 4.10, p = 0.008, CI 1.62-9.58); relatives of individuals without the G allele were not at increased risk. 30823903

2019

dbSNP: rs55829688
rs55829688
0.010 GeneticVariation BEFREE Patients with PC were recruited and grouped according to their specific genotypes of rs55829688 and rs145204276. 30317620

2019

dbSNP: rs55958994
rs55958994
0.010 GeneticVariation BEFREE Our data suggest that the rs55958994-associated enhancer affects prostate cancer progression by influencing expression of multiple genes via long-range chromatin interactions. 31328168

2019

dbSNP: rs643555
rs643555
0.010 GeneticVariation BEFREE CDH2 rs643555 may be a promising biomarker to identify patients at high risk of poor prostate cancer prognosis. 30993852

2019

dbSNP: rs6542993
rs6542993
0.010 GeneticVariation BEFREE The <i>NPAS2</i> rs6542993 polymorphism may be a promising biomarker, and may shed light on the pathways that govern prostate cancer progression. 30996687

2019

dbSNP: rs851023
rs851023
0.010 GeneticVariation BEFREE The MAPK14 gene SNP rs851023 was associated with PCa and aggressive PCa risk after multiple comparison adjustment. 31667711

2019

dbSNP: rs10175368
rs10175368
0.010 GeneticVariation BEFREE These results demonstrate smoking and alcohol consumption to modify the risks of CYP1B1 polymorphisms for prostate cancer which may be through rs10175368, and this is of importance in understanding their role in the pathogenesis and as a biomarker for this disease. 30133114

2018

dbSNP: rs1042489
rs1042489
0.010 GeneticVariation BEFREE The aim of this study was to investigate the possible association of c.-31G>C (rs9904341), c.454G>A (rs2071214), c.*148T>C (rs2239680) and c.*571T>C (rs1042489) polymorphisms of <i>survivin</i> gene with prostate cancer risk and provide some justification using <i>in silico</i> analysis. 30034311

2018

dbSNP: rs1049216
rs1049216
0.010 GeneticVariation BEFREE Specifically, the results of study seem to hint at a higher risk of PCa in smokers of up to 20 pack-years (PY) and carriers of both the CASP3-rs1049216 GG genotype and the G allele (OR = 3.61, p = 0.044; OR = 1.71; p = 0.018). 30176316

2018

dbSNP: rs1221877686
rs1221877686
0.010 GeneticVariation BEFREE While there was a trend toward an earlier age at diagnosis, overall the clinicopathologic features of PCa were not significantly different in G84E carriers and non-carriers. 29181843

2018

dbSNP: rs1646724
rs1646724
0.010 GeneticVariation BEFREE Further investigation revealed that rs1646724 may affect expression of SLC35B4, which encodes a glycosyltransferase, and that down-regulation of SLC35B4 by transfecting short hairpin RNA in DU145 human prostate cancer cell suppressed proliferation, migration and invasion. 29682886

2018

dbSNP: rs16901946
rs16901946
0.010 GeneticVariation BEFREE Moreover, four prostate cancer-associated ncRNA 1 (PRNCR1, rs16901946 G/A, rs13252298 G/A, rs1016343 T/C, and rs1456315 G/A) SNPs were in association with cancer risk. 29802154

2018

dbSNP: rs17576
rs17576
0.010 GeneticVariation BEFREE MMP polymorphisms are not associated with prostate cancer risk, except for MMP3 11715A/6A and MMP9 rs17576. 30464622

2018

dbSNP: rs1799750
rs1799750
0.010 GeneticVariation BEFREE Meta-analysis showed no associations between MMP1 rs1799750, MMP2 rs243865, or MMP7 rs11568818 and prostate cancer risk overall. 30464622

2018